EMAIL THIS PAGE TO A FRIEND

Trials

Immediate access arteriovenous grafts versus tunnelled central venous catheters: study protocol for a randomised controlled trial.


PMID 25885054

Abstract

Autologous arteriovenous fistulae (AVF) are the optimal form of vascular access for haemodialysis. AVFs typically require 6 to 8xa0weeks to "mature" from the time of surgery before they can be cannulated. Patients with end-stage renal disease needing urgent vascular access therefore traditionally require insertion of a tunnelled central venous catheter (TCVC). TCVCs are associated with high infection rates and central venous stenosis. Early cannulation synthetic arteriovenous grafts (ecAVG) provide a novel alternative to TCVCs, permitting rapid access to the bloodstream and immediate needling for haemodialysis. Published rates of infection in small series are low. The aim of this study is to compare whether TCVC ± AVF or ecAVG ± AVF provide a better strategy for managing patients requiring immediate vascular access for haemodialysis. This is a prospective randomised controlled trial comparing the strategy of TCVC ± AVF to ecAVG ± AVF. Patients requiring urgent vascular access will receive a study information sheet and written consent will be obtained. Patients will be randomised to receive either: (i) TCVC (and native AVF if this is anatomically possible) or (ii) ecAVG (± AVF). 118 patients will be recruited. The primary outcome is systemic bacteraemia at 6xa0months. Secondary outcomes include culture-proven bacteraemia rates at 1xa0year and 2xa0years; primary and secondary patency rates at 3, 6, 12 and 24xa0months; stenoses; re-intervention rates; re-admission rate; mortality and quality of life. Additionally, treatment delays, impact on service provision and cost-effectiveness will be evaluated. This is the first randomised controlled trial comparing TCVC to ecAVG for patients requiring urgent vascular access for haemodialysis. The complications of TCVC are considered an unfortunate necessity in patients requiring urgent haemodialysis who do not have autologous vascular access. If this study demonstrates that ecAVGs provide a safe and practical alternative to TCVC, this could instigate a paradigm shift in nephrology thinking and access planning. This study has been approved by the West of Scotland Research Ethics Committee 4 (reference no. 13/WS/0087, 28 August 2013) and is registered with the International Standard Randomised Controlled Trial Number Register (reference no. ISRCTN80588541 , 27 May 2014).

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

U0631
Urea, BioXtra, pH 7.5-9.5 (20 °C, 5 M in H2O)
CH4N2O
U4883
Urea, 8 M (after reconstitution with 16 mL high purity water)
CH4N2O
U6504
Urea, for electrophoresis
CH4N2O
U4884
Urea, meets USP testing specifications
CH4N2O
U4128
Urea, BioReagent, suitable for cell culture
CH4N2O
U5128
Urea, ACS reagent, 99.0-100.5%
CH4N2O
U1250
Urea, ReagentPlus®, ≥99.5%, pellets
CH4N2O
51456
Urea, BioUltra, for molecular biology, ≥99.5% (T)
CH4N2O
33247
Urea, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99.5%
CH4N2O
15604
Urea, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.0-100.5%, 99.0-101.0% (calc. on dry substance)
CH4N2O
U0600000
Urea, European Pharmacopoeia (EP) Reference Standard
CH4N2O
1706698
Urea, United States Pharmacopeia (USP) Reference Standard
CH4N2O
56180
Urea, analytical standard
CH4N2O
51465
Urea, tested according to Ph.Eur.
CH4N2O
U7129
Urea solution, 40 % (w/v) in H2O
CH4N2O
51457
Urea solution, BioUltra, ~8 M in H2O
CH4N2O
08582
Urea solution, for microbiology, 40% in H2O
CH4N2O
299367
Urea-12C, 99.9 atom % 12C
12CH4N2O
608734
Urea-14N2, 99.99 atom % 14N, 15N-depleted
CH414N2O
A2250
Warfarin, analytical standard
C19H16O4
45706
Warfarin, PESTANAL®, analytical standard
C19H16O4
1719000
Warfarin, United States Pharmacopeia (USP) Reference Standard
C19H16O4